The outlook of companies tied to the drug's legacy presents a challenging investment picture . While the initial boom generated substantial returns , generic alternatives have significantly diminished https://thejillist.com/story12058178/copyright-s-flagship-product-and-the-pharmaceutical-sector-a-speculative-investment